Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Pharma industry improves access to medicines in developing world

Writing for the Financial Times, Clive Cookson covers the Foundation’s latest research report - the first 10-year analysis on how the pharmaceutical industry has performed on global health goals. The article dives deep into the findings, reporting on where progress has been made in the last ten years and where improvements can be sustained.

Date

16 May 2019

The article sets out with an overview of how the pharmaceutical industry has made progress in the past ten years when it comes to access to medicine. It notes the growing R&D pipeline, particularly for key diseases such malaria, HIV/AIDS and tuberculosis and reports that new medicines are supported increasingly by initiatives to help patients obtain treatment in poorer countries. 

Other areas of company progress covered by the article include the number of market approvals in the last decade and the recognition of access to medicine as a strategic issue.

However, the Financial Times' article concludes with a quote from Jayasree K Iyer, Executive Director of the Access to Medicine Foundation, highlighting that progress is uneven. Only a handful of companies consistently carry the load and overall the activity concentrates on a few countries and diseases.

"We now have a workable and scalable approach for good practice in this area but we need it to be adopted in more countries by more companies for more diseases.”

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved